This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Howell, G. M. Articles by Brattain, M. G. Search for Related Content PubMed PubMed Citation Articles by Howell, G. M. Articles by Brattain, M. G.

 Previous Article  |  Next Article 

Mol. Cell. Biol., Jan 1998, 303-313, Vol 18, No. 1
Copyright © 1998, American Society for Microbiology

Regulation of transforming growth factor alpha expression in a growth factor-independent cell line

GM Howell, LE Humphrey, BL Ziober, R Awwad, B Periyasamy, A Koterba, W Li, JK Willson, K Coleman, J Carboni, M Lynch and MG Brattain
Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo 43699-0008, USA.

Aberrant transcriptional regulation of transforming growth factor alpha (TGF alpha) appears to be an important contributor to the malignant phenotype and the growth factor independence with which malignancy is frequently associated. However, little is known about the molecular mechanisms responsible for dysregulation of TGF alpha expression in the malignant phenotype. In this paper, we report on TGF alpha promoter regulation in the highly malignant growth factor-independent cell line HCT116. The HCT116 cell line expresses TGF alpha and the epidermal growth factor receptor (EGFR) but is not growth inhibited by antibodies to EGFR or TGF alpha. However, constitutive expression of TGF alpha antisense RNA in the HCT116 cell line resulted in the isolation of clones with markedly reduced TGF alpha mRNA and which were dependent on exogenous growth factors for proliferation. We hypothesized that if TGF alpha autocrine activation is the major stimulator of TGF alpha expression in this cell line, TGF alpha promoter activity should be reduced in the antisense TGF alpha clones in the absence of exogenous growth factor. This was the case. Moreover, transcriptional activation of the TGF alpha promoter was restored in an antisense-TGF alpha-mRNA- expressing clone which had reverted to a growth factor-independent phenotype. Using this model system, we were able to identify a 25-bp element within the TGF alpha promoter which conferred TGF alpha autoregulation to the TGF alpha promoter in the HCT116 cell line. In the TGF alpha-antisense-RNA-expressing clones, this element was activated by exogenous EGF. This 25-bp sequence contained no consensus sequences of known transcription factors so that the TGF alpha or EGF regulatory element within this 25-bp sequence represents a unique element. Further characterization of this 25-bp DNA sequence by deletion analysis revealed that regulation of TGF alpha promoter activity by this sequence is complex, as both repressors and activators bind in this region, but the overall expression of the activators is pivotal in determining the level of response to EGF or TGF alpha stimulation. The specific nuclear proteins binding to this region are also regulated in an autocrine-TGF alpha-dependent fashion and by exogenous EGF in EGF-deprived TGF alpha antisense clone 33. This regulation is identical to that seen in the growth factor-dependent cell line FET, which requires exogenous EGF for optimal growth. Moreover, the time response of the stimulation of trans-acting factor binding by EGF suggests that the effect is directly due to growth factor and not mediated by changes in growth state. We conclude that this element appears to represent the major positive regulator of TGF alpha expression in the growth factor-independent HCT116 cell line and may represent the major site of transcriptional dysregulation of TGF alpha promoter activity in the growth factor-independent phenotype.

This article has been cited by other articles:

• Mutsaers, A. J., Francia, G., Man, S., Lee, C. R., Ebos, J. M.L., Wu, Y., Witte, L., Berry, S., Moore, M., Kerbel, R. S. (2009). Dose-Dependent Increases in Circulating TGF-{alpha} and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent. Clin. Cancer Res. 15: 2397-2405 [Abstract] [Full Text]  
• Zhou, Y., Li, S., Hu, Y. P., Wang, J., Hauser, J., Conway, A. N., Vinci, M. A., Humphrey, L., Zborowska, E., Willson, J. K.V., Brattain, M. G. (2006). Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis. Cancer Res. 66: 404-411 [Abstract] [Full Text]  
• Zhou, Y., Brattain, M. G. (2005). Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis. Cancer Res. 65: 5848-5856 [Abstract] [Full Text]  
• Awwad, R. A., Sergina, N., Yang, H., Ziober, B., Willson, J. K. V., Zborowska, E., Humphrey, L. E., Fan, R., Ko, T. C., Brattain, M. G., Howell, G. M. (2003). The Role of Transforming Growth Factor {alpha} in Determining Growth Factor Independence. Cancer Res. 63: 4731-4738 [Abstract] [Full Text]  
• Sawhney, R. S., Sharma, B., Humphrey, L. E., Brattain, M. G. (2003). Integrin {alpha}2 and Extracellular Signal-regulated Kinase Are Functionally Linked in Highly Malignant Autocrine Transforming Growth Factor-{alpha}-driven Colon Cancer Cells. J. Biol. Chem. 278: 19861-19869 [Abstract] [Full Text]  
• Sawhney, R. S., Zhou, G.-H. K., Humphrey, L. E., Ghosh, P., Kreisberg, J. I., Brattain, M. G. (2002). Differences in Sensitivity of Biological Functions Mediated by Epidermal Growth Factor Receptor Activation with Respect to Endogenous and Exogenous Ligands. J. Biol. Chem. 277: 75-86 [Abstract] [Full Text]